MX2020011196A - Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. - Google Patents
Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.Info
- Publication number
- MX2020011196A MX2020011196A MX2020011196A MX2020011196A MX2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A
- Authority
- MX
- Mexico
- Prior art keywords
- indacen
- hexahydro
- sulfonamide
- pyrazole
- isopropyl
- Prior art date
Links
- 159000000000 sodium salts Chemical class 0.000 title abstract 2
- -1 1,2,3,5,6,7-hexahydro-s-indacen-4-yl Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- MTOUOUSKXWSTAX-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-(1-propan-2-ylpyrazol-3-yl)sulfonylurea Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)NS(=O)(=O)C1=NN(C=C1)C(C)C MTOUOUSKXWSTAX-UHFFFAOYSA-N 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a una sal sódica de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1 H-pirazol-3-sulfonamida y a hidratos, solvatos y formas polimórficas de estos. La presente invención se refiere además a composiciones farmacéuticas que comprenden este compuesto y al uso de este compuesto en el tratamiento y la prevención de trastornos y enfermedades médicos, más especialmente por inhibición de NLRP3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806578.9A GB201806578D0 (en) | 2018-04-23 | 2018-04-23 | Novel compound |
| PCT/EP2019/060311 WO2019206871A1 (en) | 2018-04-23 | 2019-04-23 | A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011196A true MX2020011196A (es) | 2020-11-13 |
Family
ID=62236309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011196A MX2020011196A (es) | 2018-04-23 | 2019-04-23 | Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10973803B2 (es) |
| EP (2) | EP3722281A1 (es) |
| JP (1) | JP7382958B2 (es) |
| KR (1) | KR20210005589A (es) |
| CN (1) | CN112020495B (es) |
| AR (1) | AR114827A1 (es) |
| AU (1) | AU2019257973A1 (es) |
| BR (1) | BR112020021650A2 (es) |
| CA (1) | CA3097832A1 (es) |
| CY (1) | CY1123260T1 (es) |
| DK (1) | DK3606909T3 (es) |
| ES (1) | ES2811228T3 (es) |
| GB (1) | GB201806578D0 (es) |
| HR (1) | HRP20201263T1 (es) |
| HU (1) | HUE050369T2 (es) |
| LT (1) | LT3606909T (es) |
| MA (2) | MA51082A (es) |
| MD (1) | MD3606909T2 (es) |
| ME (1) | ME03822B (es) |
| MX (1) | MX2020011196A (es) |
| PL (1) | PL3606909T3 (es) |
| PT (1) | PT3606909T (es) |
| RS (1) | RS60646B1 (es) |
| SI (1) | SI3606909T1 (es) |
| SM (1) | SMT202000448T1 (es) |
| TW (1) | TW201943704A (es) |
| UY (1) | UY38186A (es) |
| WO (1) | WO2019206871A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55695A (fr) | 2017-01-23 | 2022-02-23 | Genentech Inc | Composés chimiques comme inhibiteurs de l'activité interleukine-1 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| UY37847A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| WO2019034692A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MA49904A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| EP3707137A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| BR112020008981A2 (pt) | 2017-11-09 | 2020-11-17 | Inflazome Limited | novos compostos de sulfonamida carboxamida |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| EP3759073A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| WO2019166629A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| EP3823726A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche SA | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20220401414A1 (en) * | 2019-11-07 | 2022-12-22 | Inflazome Limited | Treatment and prevention of a neurodegenerative disorder |
| CN114599356A (zh) * | 2019-11-07 | 2022-06-07 | 英夫拉索姆有限公司 | 自身炎症性病症的治疗 |
| WO2021089776A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of a traumatic brain disorder |
| WO2021089769A1 (en) | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of neuroinflammation or an inflammatory brain disorder |
| GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
| WO2021089781A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4802908A (en) * | 1987-01-22 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2-(1H)-pyrazinones |
| WO2001019390A1 (en) * | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| EP2781216A4 (en) * | 2011-09-02 | 2015-05-27 | Kyowa Hakko Kirin Co Ltd | CHEMOKINREZEPTORAKTIVITÄTSREGLER |
| SI3578547T1 (sl) | 2015-02-16 | 2021-09-30 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| WO2017140778A1 (en) | 2016-02-16 | 2017-08-24 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| MA44734A (fr) | 2016-04-18 | 2021-05-19 | Novartis Ag | Composés et compositions destinés au traitement d'états associés à une activité de nlrp |
| EP3445756B1 (en) | 2016-04-18 | 2022-07-06 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
-
2018
- 2018-04-23 GB GBGB1806578.9A patent/GB201806578D0/en not_active Ceased
-
2019
- 2019-04-23 PL PL19721230T patent/PL3606909T3/pl unknown
- 2019-04-23 ES ES19721230T patent/ES2811228T3/es active Active
- 2019-04-23 EP EP20176198.8A patent/EP3722281A1/en not_active Withdrawn
- 2019-04-23 CA CA3097832A patent/CA3097832A1/en active Pending
- 2019-04-23 BR BR112020021650-0A patent/BR112020021650A2/pt not_active Application Discontinuation
- 2019-04-23 JP JP2020557902A patent/JP7382958B2/ja active Active
- 2019-04-23 MD MDE20200181T patent/MD3606909T2/ro not_active IP Right Cessation
- 2019-04-23 MX MX2020011196A patent/MX2020011196A/es unknown
- 2019-04-23 TW TW108114167A patent/TW201943704A/zh unknown
- 2019-04-23 LT LTEP19721230.1T patent/LT3606909T/lt unknown
- 2019-04-23 RS RS20200936A patent/RS60646B1/sr unknown
- 2019-04-23 AR ARP190101056A patent/AR114827A1/es not_active Application Discontinuation
- 2019-04-23 EP EP19721230.1A patent/EP3606909B1/en active Active
- 2019-04-23 HR HRP20201263TT patent/HRP20201263T1/hr unknown
- 2019-04-23 DK DK19721230.1T patent/DK3606909T3/da active
- 2019-04-23 WO PCT/EP2019/060311 patent/WO2019206871A1/en not_active Ceased
- 2019-04-23 HU HUE19721230A patent/HUE050369T2/hu unknown
- 2019-04-23 AU AU2019257973A patent/AU2019257973A1/en not_active Abandoned
- 2019-04-23 SI SI201930005T patent/SI3606909T1/sl unknown
- 2019-04-23 MA MA051082A patent/MA51082A/fr unknown
- 2019-04-23 ME MEP-2020-173A patent/ME03822B/me unknown
- 2019-04-23 MA MA48051A patent/MA48051B1/fr unknown
- 2019-04-23 CN CN201980026640.0A patent/CN112020495B/zh active Active
- 2019-04-23 SM SM20200448T patent/SMT202000448T1/it unknown
- 2019-04-23 PT PT197212301T patent/PT3606909T/pt unknown
- 2019-04-23 KR KR1020207030023A patent/KR20210005589A/ko not_active Ceased
- 2019-04-23 UY UY0001038186A patent/UY38186A/es not_active Application Discontinuation
-
2020
- 2020-04-16 US US16/850,978 patent/US10973803B2/en active Active
- 2020-08-12 CY CY20201100756T patent/CY1123260T1/el unknown
-
2021
- 2021-03-09 US US17/196,956 patent/US20210315862A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011196A (es) | Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. | |
| MX2021004431A (es) | Procesos novedosos. | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MY210086A (en) | Pharmaceutical compounds | |
| MX2023010411A (es) | Inhibidores de erbb/btk. | |
| JOP20190229B1 (ar) | مركبات تثبط بروتين mcl-1 | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| MX2021004582A (es) | Compuesto 2-azabiciclo hexano inhibidor de jak. | |
| MX2020010805A (es) | Inhibidores de bcl6. | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| MY199779A (en) | Pyrrolopyrimidine compound and use thereof | |
| PH12021550554A1 (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| MX2023014547A (es) | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
| MX2023015377A (es) | Sal de potasio cristalina de 1-etil-n-((1,2,3,5,6,7-hexahidro-s-in dacen-4-il)carbamoil)piperidin-4-sulfonamida. | |
| MX2021005944A (es) | Inhibidores de rip1. | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors |